Literature DB >> 19670957

Medicare part D after 2 years.

Geoffrey F Joyce1, Dana P Goldman, William B Vogt, Eric Sun, Anupam B Jena.   

Abstract

OBJECTIVE: To assess the broad impacts of Medicare Part D and the extent to which prior concerns have been realized.
METHODS: We used administrative data to summarize beneficiary enrollment and plan participation in Part D, and compared pharmaceutical use and out-of-pocket spending before and after the introduction of Part D. We characterized the benefit designs of the 10 largest Part D plans in 2006 and compared them with the benefit designs of 7 non-Part D plans often cited as examples of low-cost or comprehensive drug benefits.
RESULTS: By 2008, nearly 90% of seniors had drug coverage at least as generous as the standard Part D benefit. Excluding premiums, annual out-of-pocket spending in the 10 largest Part D plans was comparable to that of other private and public drug benefits, with the most prominent differences attributable to out-of-pocket spending on drugs not covered in the plan. Poorer beneficiaries have gained the most from Part D in terms of increased access to medications and reduced out-of-pocket spending.
CONCLUSIONS: Coverage under Part D is comparable to that under non-Part D plans with respect to key features that are likely to be important to Medicare beneficiaries--access to medications and out-of-pocket costs. Nonetheless, concerns remain over drug pricing and gaps in coverage. The government should continue to monitor the competitiveness of the Part D market to ensure it meets the diverse needs of Medicare beneficiaries.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19670957      PMCID: PMC3767434     

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  11 in total

1.  Medicare prescription drug coverage: consumer information and preferences.

Authors:  Joachim Winter; Rowilma Balza; Frank Caro; Florian Heiss; Byung-hill Jun; Rosa Matzkin; Daniel McFadden
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-08       Impact factor: 11.205

2.  Status report on Medicare Part D enrollment in 2006: analysis of plan-specific market share and coverage.

Authors:  Juliette Cubanski; Patricia Neuman
Journal:  Health Aff (Millwood)       Date:  2006-11-21       Impact factor: 6.301

3.  The impact of Medicare Part D on prescription drug use by the elderly.

Authors:  Frank R Lichtenberg; Shawn X Sun
Journal:  Health Aff (Millwood)       Date:  2007 Nov-Dec       Impact factor: 6.301

4.  Medicare beneficiaries' knowledge of Part D prescription drug program benefits and responses to drug costs.

Authors:  John Hsu; Vicki Fung; Mary Price; Jie Huang; Richard Brand; Rita Hui; Bruce Fireman; Joseph P Newhouse
Journal:  JAMA       Date:  2008-04-23       Impact factor: 56.272

5.  Cost-related medication nonadherence and spending on basic needs following implementation of Medicare Part D.

Authors:  Jeanne M Madden; Amy J Graves; Fang Zhang; Alyce S Adams; Becky A Briesacher; Dennis Ross-Degnan; Jerry H Gurwitz; Marsha Pierre-Jacques; Dana Gelb Safran; Gerald S Adler; Stephen B Soumerai
Journal:  JAMA       Date:  2008-04-23       Impact factor: 56.272

6.  Pharmacy benefit caps and the chronically ill.

Authors:  Geoffrey F Joyce; Dana P Goldman; Pinar Karaca-Mandic; Yuhui Zheng
Journal:  Health Aff (Millwood)       Date:  2007 Sep-Oct       Impact factor: 6.301

7.  Effects of a limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia.

Authors:  S B Soumerai; T J McLaughlin; D Ross-Degnan; C S Casteris; P Bollini
Journal:  N Engl J Med       Date:  1994-09-08       Impact factor: 91.245

8.  The effect of the Medicare Part D prescription benefit on drug utilization and expenditures.

Authors:  Wesley Yin; Anirban Basu; James X Zhang; Atonu Rabbani; David O Meltzer; G Caleb Alexander
Journal:  Ann Intern Med       Date:  2008-01-07       Impact factor: 25.391

Review 9.  Prescription drug cost sharing: associations with medication and medical utilization and spending and health.

Authors:  Dana P Goldman; Geoffrey F Joyce; Yuhui Zheng
Journal:  JAMA       Date:  2007-07-04       Impact factor: 56.272

10.  Reporting of drug expenditures in the MCBS.

Authors:  John A Poisal
Journal:  Health Care Financ Rev       Date:  2003
View more
  6 in total

1.  Medicare Part D plan generosity and medication use among dual-eligible nursing home residents.

Authors:  Haiden A Huskamp; David G Stevenson; A James O'Malley; Stacie B Dusetzina; Susan L Mitchell; Barbara J Zarowitz; Michael E Chernew; Joseph P Newhouse
Journal:  Med Care       Date:  2013-10       Impact factor: 2.983

2.  The impact of Medicare Part D on out-of-pocket costs for prescription drugs, medication utilization, health resource utilization, and preference-based health utility.

Authors:  Frank Xiaoqing Liu; G Caleb Alexander; Stephanie Y Crawford; A Simon Pickard; Donald Hedeker; Surrey M Walton
Journal:  Health Serv Res       Date:  2011-05-24       Impact factor: 3.402

Review 3.  Changes in drug use and out-of-pocket costs associated with Medicare Part D implementation: a systematic review.

Authors:  Jennifer M Polinski; Elaine Kilabuk; Sebastian Schneeweiss; Troyen Brennan; William H Shrank
Journal:  J Am Geriatr Soc       Date:  2010-09       Impact factor: 5.562

4.  Medicare part D's impact on antipsychotic drug use and costs among elderly patients without prior drug insurance.

Authors:  Jennifer M Polinski; M Alan Brookhart; Robert J Glynn; Sebastian Schneeweiss
Journal:  J Clin Psychopharmacol       Date:  2012-02       Impact factor: 3.153

5.  Effects of Medicare Part D on drug affordability and use: Are seniors with prior high out-of-pocket drug spending affected more?

Authors:  David A Mott; Joshua M Thorpe; Carolyn T Thorpe; David H Kreling; Abhijit S Gadkari
Journal:  Res Social Adm Pharm       Date:  2010-06

6.  Digesting the doughnut hole.

Authors:  Geoffrey F Joyce; Julie Zissimopoulos; Dana P Goldman
Journal:  J Health Econ       Date:  2013-05-06       Impact factor: 3.883

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.